OUR MISSION

We strive to treat more patients with ground-breaking therapies. This mission inspires and motivates us.

STRATEGY FOR VALUE CREATION

Actelion’s strategy is designed to create value by leveraging the Company’s many strengths. These include its global leadership in the field of pulmonary arterial hypertension (PAH) therapy, a strong and effective worldwide specialty commercial organization, a highly productive discovery capability and a unique company culture that focuses on delivering innovative medicines that improve patient’s lives.

We are the leaders in PAH therapy and, with our PAH products, we will continue to lead well into the future. During this time we must build our portfolio – through R&D and/or business development, to find additional meaningfully differentiated products to benefit patients. To realize our potential, we need to have a solid business – which means never losing sight of spending, whilst maintaining quality in all that we do.

Strategic principles

 
Actelion - Shaping Our Future

Strategic Principles

Total employees

Drug Discovery366
Clinical Development440
Marketing & Sales1,432
Support Functions322
Total2,560
June  2016

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 13:43:18 CET 17/01/2017
CHF 230,30Up Down image
-0,30 (-0,13%)
 

Medical Science Liaison, UK 

 

"Actelion is different because of its commitment to science, and the search for new ideas and solutions for health problems."